Latest Breaking News On - Robertj deluccia - Page 3 : comparemela.com

Acurx Pharmaceuticals Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C difficile Infection

Based on observed aggregate blinded data the Company has determined that both treatments, ibezapolstat and the control antibiotic vancomycin, have performed as.

United statesDavidp luciRobertj delucciaData monitoring committeeInfectious diseases society of americaSociety for healthcare epidemiology of americaTrial oversight committeeDrug administrationPrnewswire acurx pharmaceuticals incCompany annual report on formAcurx pharmaceuticalsExchange commissionAcurx pharmaceuticals incClinical cureFast track designatedIndependent data monitoring committee

Acurx Announces Presentation and Update of Its pol IIIC R&D Pipeline at the World Antimicrobial Resistance Scientific Congress

Ibezapolstat is currently enrolling in a Phase 2b trial for C. difficile infection in U.S. centers across the country and nearing its goal to reach a targeted.

United statesRobertj delucciaData monitoring committeeCompany phSociety or healthcare epidemiology of americaAcurx pharmaceuticals incExchange commissionTrial oversight committeeWorld antimicrobial resistance congressExchange commission on formDrug administrationAcurx pharmaceuticalsPrnewswire acurx pharmaceuticals incWorld antimicrobial resistance scientific congress onInfectious diseases society of americaInterim analysis

Acurx Announces Ibezapolstat Scientific Poster and Update on its Pol IIIC Pipeline Presented at ECCMID 2023 Scientific Conference

/PRNewswire/ Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of.

United statesRobertj delucciaUrsula theuretzbacherKevin gareyData monitoring committeeCompany phDrug administrationUniversity of houstonExchange commission on formSociety or healthcare epidemiology of americaInfectious diseases society of americaEuropean society of clinical microbiologyResearch scientist facultyAcurx pharmaceuticals incAcurx pharmaceuticalsUniversity of houston college pharmacy

FDA Accepts Interim Analysis Plan for Ongoing Phase 2b Ibezapolstat Clinical Trial and Acurx Announces Presentations at ECCMID 2023 Scientific Conference

FDA has accepted an Interim Analysis Plan for an IDMC to assess clinical outcome when 36 patients are enrolled in the Company s Ph2b clinical trial of.

United statesKevin gareyUrsula theuretzbacherRobertj delucciaEuropean society of clinical microbiologyExchange commission on formEuropean congressPrnewswire acurx pharmaceuticals incCompany phInfectious diseases society of americaDrug administrationExchange commissionAcurx pharmaceuticals incTrial oversight committeeUniversity of houston college pharmacyAcurx pharmaceuticals

Acurx Pharmaceuticals (ACXP) Announces FDA Accepts Interim Analysis Plan for Ongoing Phase 2b Ibezapolstat Clinical Trial

Acurx Pharmaceuticals (ACXP) Announces FDA Accepts Interim Analysis Plan for Ongoing Phase 2b Ibezapolstat Clinical Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesKevin gareyRobertj delucciaUrsula theuretzbacherData monitoring committeeInfectious diseases society of americaInhibitor program for systemic bacterialAcurx pharmaceuticalsUniversity of houston college pharmacyDrug administrationAcurx pharmaceuticals incCompany phEuropean society of clinical microbiologyEuropean congressTrial oversight committeeSociety or healthcare epidemiology of america